LIVE UPDATES: Fed Chair Jerome Powell to deliver major speech at Jackson Hole
In a recent transaction, James L. Bierman, a director at Tenet Healthcare Corp (NYSE:THC), sold shares of the company’s common stock valued at approximately $784,210. The sale comes as the healthcare provider, with a market capitalization of $15.75 billion, trades near its 52-week high of $171.20, having delivered an impressive 33.7% return year-to-date. According to InvestingPro analysis, the stock’s RSI indicates overbought territory. The sale, conducted on May 29, involved 4,613 shares at a price of $170 each. This transaction was executed under a prearranged 10b5-1 trading plan, which allows insiders to set up a predetermined plan for selling stocks in compliance with insider trading laws. Following this sale, Bierman retains ownership of 35,271 shares of Tenet Healthcare. Notably, 14 analysts have recently revised their earnings expectations upward for the upcoming period, and InvestingPro subscribers can access 12 additional key insights about THC’s financial health and market position.
In other recent news, Tenet Healthcare has been the focus of several analyst updates and corporate developments. BofA Securities raised its price target for Tenet Healthcare to $180, maintaining a Buy rating, following insights shared by the company’s leadership at a recent conference. The company’s strategic focus on expanding its Ambulatory Surgery Center (ASC) business was highlighted as a key growth area. Meanwhile, Goldman Sachs increased its price target to $154 while keeping a Neutral rating, citing Tenet’s solid fundamentals and effective cost management in its Hospital segment.
Cantor Fitzgerald also reaffirmed its Overweight rating on Tenet Healthcare with a price target of $177, noting stable physician openings and controlled hiring trends. The firm pointed out Tenet’s robust performance and attractive financial guidance despite political uncertainties. Additionally, Tenet Healthcare held its 2025 Annual Meeting of Shareholders, where all nominated directors were elected, and executive compensation was approved with substantial shareholder support.
The meeting also saw the ratification of Deloitte & Touche LLP as the company’s independent auditors. However, a shareholder proposal on maternal health outcomes did not pass. These developments reflect Tenet Healthcare’s strategic direction and investor confidence in its governance and financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.